Business
Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.